Ventas, Inc. VTR
We take great care to ensure that the data presented and summarized in this overview for Ventas, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VTR
View all-
Vanguard Group Inc Valley Forge, PA71.8MShares$4.99 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY43.3MShares$3.01 Billion0.05% of portfolio
-
Jpmorgan Chase & CO New York, NY32.3MShares$2.25 Billion0.17% of portfolio
-
State Street Corp Boston, MA28MShares$1.95 Billion0.07% of portfolio
-
Principal Financial Group Inc Des Moines, IA15.8MShares$1.1 Billion0.57% of portfolio
-
Geode Capital Management, LLC Boston, MA12.2MShares$850 Million0.06% of portfolio
-
Apg Asset Management Us Inc. New York, NY11.8MShares$818 Million5.68% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.61MShares$529 Million0.05% of portfolio
-
Centersquare Investment Management LLC Plymouth Meeting, PA7.01MShares$487 Million4.72% of portfolio
-
Resolution Capital LTD Sydney, Nsw, C36.97MShares$485 Million8.74% of portfolio
Latest Institutional Activity in VTR
Top Purchases
Top Sells
About VTR
Ventas, an S&P 500 company, operates at the intersection of two powerful and dynamic industries ? healthcare and real estate. As one of the world's foremost Real Estate Investment Trusts (REIT), we use the power of capital to unlock the value of real estate, partnering with leading care providers, developers, research and medical institutions, innovators and healthcare organizations whose success is buoyed by the demographic tailwind of an aging population. For more than twenty years, Ventas has followed a successful strategy that endures: combining a high-quality diversified portfolio of properties and capital sources to manage through cycles, working with industry leading partners, and a collaborative and experienced team focused on producing consistent growing cash flows and superior returns on a strong balance sheet, ultimately rewarding Ventas shareholders. As of September 30, 2020, Ventas owned or managed through unconsolidated joint ventures approximately 1,200 properties.
Insider Transactions at VTR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 16
2025
|
Melody C Barnes Director |
BUY
Grant, award, or other acquisition
|
Direct |
74
+0.22%
|
$5,106
$69.55 P/Share
|
Oct 16
2025
|
Michael J Embler Director |
BUY
Grant, award, or other acquisition
|
Direct |
74
+0.51%
|
$5,106
$69.55 P/Share
|
Oct 16
2025
|
Matthew J Lustig Director |
BUY
Grant, award, or other acquisition
|
Direct |
324
+0.18%
|
$22,356
$69.55 P/Share
|
Oct 16
2025
|
Roxanne M Martino Director |
BUY
Grant, award, or other acquisition
|
Direct |
201
+0.32%
|
$13,869
$69.55 P/Share
|
Oct 16
2025
|
Marguerite M Nader Director |
BUY
Grant, award, or other acquisition
|
Direct |
74
+0.35%
|
$5,106
$69.55 P/Share
|
Oct 16
2025
|
Joe Vasquez Rodriguez Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
46
+0.59%
|
$3,174
$69.55 P/Share
|
Oct 16
2025
|
Sumit Roy Director |
BUY
Grant, award, or other acquisition
|
Direct |
123
+0.29%
|
$8,487
$69.55 P/Share
|
Oct 16
2025
|
Maurice S Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
133
+0.24%
|
$9,177
$69.55 P/Share
|
Oct 01
2025
|
Peter J. Bulgarelli EVP OM&R-Ventas/Pres&CEO-LHS |
SELL
Open market or private sale
|
Direct |
2,554
-2.15%
|
$178,780
$70.26 P/Share
|
Oct 01
2025
|
Debra A Cafaro Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,322
-0.89%
|
$722,540
$70.24 P/Share
|
Oct 01
2025
|
Debra A Cafaro Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,322
+0.89%
|
$670,930
$65.45 P/Share
|
Oct 01
2025
|
Matthew J Lustig Director |
BUY
Grant, award, or other acquisition
|
Direct |
462
+0.5%
|
$32,340
$70.32 P/Share
|
Oct 01
2025
|
Roxanne M Martino Director |
BUY
Grant, award, or other acquisition
|
Direct |
728
+1.16%
|
$50,960
$70.32 P/Share
|
Oct 01
2025
|
Sumit Roy Director |
BUY
Grant, award, or other acquisition
|
Direct |
444
+2.05%
|
$31,080
$70.32 P/Share
|
Oct 01
2025
|
Maurice S Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
533
+1.91%
|
$37,310
$70.32 P/Share
|
Sep 30
2025
|
Peter J. Bulgarelli EVP OM&R-Ventas/Pres&CEO-LHS |
SELL
Open market or private sale
|
Direct |
2,040
-1.68%
|
$140,760
$69.99 P/Share
|
Sep 15
2025
|
Peter J. Bulgarelli EVP OM&R-Ventas/Pres&CEO-LHS |
SELL
Open market or private sale
|
Direct |
406
-0.33%
|
$28,420
$70.0 P/Share
|
Sep 02
2025
|
Debra A Cafaro Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,322
-0.89%
|
$691,574
$67.8 P/Share
|
Sep 02
2025
|
Debra A Cafaro Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,322
+0.89%
|
$670,930
$65.45 P/Share
|
Aug 04
2025
|
Robert F Probst EVP and CFO |
SELL
Open market or private sale
|
Direct |
29,691
-14.99%
|
$2,018,988
$68.49 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 579K shares |
---|---|
Exercise of conversion of derivative security | 900K shares |
Payment of exercise price or tax liability | 213K shares |
---|---|
Bona fide gift | 10K shares |
Open market or private sale | 966K shares |